A. Ephraim

DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma

A. Kruisbeek, J. Rosenblatt, D. Avigan, 2017, Journal of immunotherapy.

Personalized tumor vaccine for pancreatic cancer

M. Hidalgo, D. Kufe, S. Muthuswamy, 2022, Cancer Immunology, Immunotherapy.

MUC1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism

D. Kufe, E. Anastasiadou, M. Bar‐Natan, 2018, Journal of cellular and molecular medicine.

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

F. Slack, D. Tenen, D. Kufe, 2017, Leukemia.

Personalized tumor vaccine for pancreatic cancer

M. Hidalgo, D. Kufe, S. Muthuswamy, 2022, Cancer Immunology, Immunotherapy.

Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine

F. Slack, D. Kufe, E. Anastasiadou, 2019, British journal of haematology.